SHANGHAI – The Center for Drug Evaluation (CDE) of the China Food and Drug Administration (CFDA) has released its annual report for 2013 which reveals only small gains have been made to fix the slow and overcrowded approval process.
HONG KONG – Chinese scientists have developed a human liver cancer cell line that replicates the entire life cycle of both the hepatitis B and hepatitis C viruses, providing a powerful tool with which to study the natural history of these pathogens and help in developing new antivirals and vaccines.
TAIPEI, TAIWAN – Neurovive Pharmaceutical AB’s Hong Kong-registered subsidiary, Neurovive Pharmaceutical Asia Ltd., has signed a financial services agreement with Yuanta Securities Co. Ltd. for the Taiwanese company to be its underwriter in a planned initial public offering (IPO) in Taiwan.
HONG KONG – Crystalgenomics Inc. released positive phase III clinical trial results for its non-steroidal anti-inflammatory drug (NSAID) polmacoxib for osteoarthritis.
SHANGHAI – In 2013, venture capital (VC) activity in China’s life sciences sector remained strong, dipping only slightly below the year previous. Investor enthusiasm did not diminish even when China barred companies from holding initial public offerings (IPO) here, the exit of choice for VCs.
HONG KONG – A listed Chinese medical diagnostic service provider and a South Korean investment company have launched a new fund to target biopharmaceutical and health care companies.
SINGAPORE – Aware that Asian markets are growing fast and will account for half of global GDP in a few decades, national and multinational biopharmaceutical firms are looking to expand their presence in the region while stepping up their innovative capabilities.
Fearing that India’s lax attitudes toward drug patents might spread to other developing countries, U.S. drugmakers want the U.S. Trade Representative (USTR) to make an example of the country by once again branding it the worst of the worst in not honoring intellectual property (IP) rights.
SHANGHAI – Bayer AG’s recent purchase of traditional Chinese medicine (TCM) maker Dihon Pharmaceutical Group Co. was viewed by some as a step closer to the legitimization of the TCM drug market, one that occupies about a third to a half of all revenues here.
RSS